Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

Keywords

Glatiramer acetate, Medicine, Placebo, Multiple sclerosis, Clinical trial

References

• Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE.Zeev Lando, Dvora Teitelbaum, Ruth Arnon — 1979
• Autosomal dominant cerebellar phenotypesRoger N. Rosenberg — 1990
• A placebo‐controlled, double‐blind, randomized, two‐center, pilot trial of Cop 1 in chronic progressive multiple sclerosisMurray B. Bornstein, A. Miller, Susan Slagle — 1991
• Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisK. P. Johnson, Benjamin Brooks, J. A. Cohen — 1995
• An evaluation of ambulatory, cassette EEG monitoringRobert Leroy, John S. Ebersole — 1983
• Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.Masha Fridkis‐Hareli, Dvora Teitelbaum, E Gurevich — 1994
• Rating neurologic impairment in multiple sclerosisJohn F. Kurtzke — 1983
• The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.Marcelo Kremenchutzky, David A. Cottrell, George P. Rice — 1999
• Severe nonfluency in aphasia. Role of the medial subcallosal fasciculus and other white matter pathways in recovery of spontaneous speech.Margaret A. Naeser, Carole L. Palumbo, Nancy Helm‐Estabrooks — 1989
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisLawrence D. Jacobs, Diane L. Cookfair, Richard A. Rudick — 1996
• Clinical scales for multiple sclerosis.Basil Sharrack, Richard A. C. Hughes — 1996
• Design strategies in multiple sclerosis clinical trials. The Cyclosporine Multiple Sclerosis Study Group.George W. Ellison, Lawrence W. Myers, Barbara Leake — 1994
• The next frontier in Parkinson's diseaseJ. William Langston, William C. Koller — 1991
• CHAPTER 3 – Experimental Models of Human Autoimmune Disease: Overview and PrototypesC. Bernard — 1992
• Genetic heterogeneity in leigh syndromeS. Dimauro, D. D. De Vivo — 1996

Cited by

• Glatiramer Acetate or Interferon-β for Multiple Sclerosis?Ron Milo, Hillel Panitch — 1999
• The cellular immunology of multiple sclerosis美治 荒井, 恭子 日比, 規子 水島 — 1999
• Predicting multiple sclerosis at optic neuritis onsetYa-Ping Jin, Jesús de Pedro-Cuesta, Y H Huang — 2003
• Glatiramer acetate in multiple sclerosis: a review.José Manuel Busto Lago — 2007
• Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosisJavier Garcia Solera, Débora Domingo Calabuig — 2015
• [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].Н. А. Спирин, D. S. Kasatkin, Stepanov Io — 2012
• Cost sharing, benefit design, and adherence: the case of multiple sclerosis.Avi Dor, Maureen J. Lage, Marcy Tarrants — 2010
• Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.Tjalf Ziemssen — 2004
• Women’s Experiences of Managing Relapsing-Remitting Multiple Sclerosis with Disease Modifying Drugs: A DissertationE. Terrill — 2007
• An investigation of magnetization transfer ratio and T1 hypointense lesion volume in secondary progressive multiple sclerosisThomas Hayton — 2012
• Assessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosisV. Anderson — 2008
• Future immunotherapies in multiple sclerosis.Gregg Blevins, Roland Martinꝉ — 2003
• Immunotherapy in autoimmune diseases.Kok Yong Fong — 2002
• Drug Class Review: Disease-modifying Drugs for Multiple SclerosisBeth Smith, Susan Carson, Rochelle Fu — 2010
• MULTIPLE SCLEROSIS: NEW PATHOPHYSIOLOGICAL AND THERAPEUTIC CONCEPTSS. J. M. Weatherby, Clive Hawkins — 2001
• The current landscape and unmet needs in multiple sclerosis.Clyde Markowitz — 2010
• GLATIRAMER ACETATE (COPAXONE)Yang Mao-Draayer, Hillel S. Panitch — 2001
• Incidence de la sclérose en plaques en Lorraine : fatigue et autres facteurs d'incapacité dans la cohorte LORSEPM. Debouverie — 2006
• Multiple sclerosis and pregnancy: pregnancy, delivery and birth outcome in woman with multiple sclerosisJulie Dahl — 2008
• Novel MR image analysis strategies: applications in multiple sclerosisN. Gabor — 2003

Related papers

• [Multiple sclerosis: current therapies and future perspectives].Takuya Matsushita — 2011
• Clinical course of multiple sclerosis in Japanese patients treated with glatiramer acetateTakako Okamoto, Youwei Lin, M. Araki — 2017
• Ischemic skin necrosis caused by glatiramer acetate in multiple sclerosis patientsRaquel Samões, Sandrina Carvalho, Rosário Alves — 2014
• Glatiramer in the treatment of multiple sclerosisSyed Rizvi, Edward Kim, Jennifer Moodie — 2006
• Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MSNaila Makhani, Bo‐Yee Ngan, Binita M. Kamath — 2013
• Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 yearsK. P. Johnson, Benjamin Brooks, Corey C. Ford — 2000
• United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.Jerry S. Wolinsky, Ponnada A. Narayana, K. P. Johnson — 2001
• 多発性硬化症における免疫病態とグラチラマー酢酸塩（コパキソン®皮下注20 mgシリンジ）の免疫調整作用Kazumasa Yokoyama, Nobutaka Hattori — 2016
• Overview of treatment options in multiple sclerosis.Emmanuelle Waubant — 2012
• Why treat early multiple sclerosis patients?Giancarlo Comi — 2000